Moxidectin

Active ingredient: Moxidectin

In short: Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulusin adult and pediatric patients aged 4 years and older and weighing at least 13 kg . Limitations of Use: Moxidectin Tablets does not kill adult Onchocerca volvulus (O.

Forms & strengthsMoxidectin Tablets: 2 mg of moxidectin, white to pale yellow, uncoated, oval-shaped, debossed on one side with “AKKA”.
LabelMedicines Development for Global Health
Label updatedAug 03, 2026

What is Moxidectin used for?

Moxidectin Tablets are indicated for the treatment of onchocerciasis due to

Onchocerca volvulusin adult and pediatric patients aged 4 years and older and weighing at least 13 kg

.

Limitations of Use:

Moxidectin Tablets does not kill adult

Onchocerca volvulus (O. volvulus) parasites

. Follow-up evaluation is advised.

The safety and efficacy of repeat administration of Moxidectin Tablets in patients with

O

.

volvulushas not been studied.

Moxidectin dosage

The recommended dosage of Moxidectin Tablets in adult patients is a single dose of 8 mg (four 2 mg tablets) taken orally with or without food

.

The recommended dosage of Moxidectin Tablets in pediatric patients aged 4 years and older and weighing at least 13 kg is described in Table 1 below. Administer Moxidectin Tablets as a single dose taken orally with or without food .

Table 1: Recommended Dosage of Moxidectin Tablets in Pediatric Patients 4 Years of Age and Older and Weighing at Least 13 kg

Body Weight | Dose | Number of 2 mg Tablets

13 kg to less than 15 kg | 4 mg | 2

15 kg to less than 30 kg | 6 mg | 3

Greater than or equal to 30 kg | 8 mg | 4

How to take Moxidectin — instructions & advice from the label

Signs and Symptoms Associated with Microfilarial Death

Advise patients that they are likely to have flu like symptoms including malaise, myalgia, headache, tachycardia, hypotension and pruritus, most commonly during the first week after treatment.

.

Symptomatic Orthostatic Hypotension

Advise patients that if they feel dizzy, faint or light-headed after taking Moxidectin Tablets, they should lie down until the symptoms resolve.

.

Absence of Macrofilarial Activity

Advise patients that treatment with Moxidectin Tablets does not kill adult

O

.

volvulusand that follow up evaluation is usually required.

Edema

and Worsening

of Onchodermatitis

Advise patients with hyper-reactive onchodermatitis that they may be more likely to experience severe adverse reactions.

.

Encephalopathy in

Loa loa

Co-infected Patients

Advise patients to report any symptoms of encephalopathy to their healthcare provider.

.

Lactation

Advise women that breastfeeding is not recommended at the time of treatment with Moxidectin Tablets and for 7 days after treatment.

.

Manufactured for: Medicines Development for Global Health, Melbourne, Victoria, Australia

© 2025 Medicines Development for Global Health. …

Warnings & precautions

Do not take this medicine if: None.

Treatment with Moxidectin Tablets may cause cutaneous, ophthalmological and/or systemic reactions of varying severity (Mazzotti reaction). These adverse reactions are due to allergic and inflammatory host responses to the death of microfilariae

.There is a trend toward an increased incidence of these adverse reactions in patients with higher microfilarial burden.

The clinical manifestations of Mazzotti reaction include pruritus, headache, pyrexia, rash, urticaria, hypotension (including symptomatic orthostatic hypotension and dizziness) , tachycardia, edema, lymphadenopathy, arthralgia, myalgia, chills, paresthesia and asthenia. Ophthalmological manifestations include conjunctivitis, eye pain, eye pruritus, eyelid swelling, blurred vision, photophobia, changes in visual acuity, hyperemia, ocular discomfort and watery eyes. These adverse reactions generally occur and resolve in the first week post-treatment. Laboratory changes include eosinophilia, eosinopenia, lymphocytopenia, neutropenia, and increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT) and lactate dehydrogenase (LDH). Proteinuria has also been reported.

Treatment of severe Mazzotti reactions has not been evaluated in controlled clinical trials. Symptomatic treatments such as oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat orthostatic hypotension. Antihistamines and/or analgesics have been used for most mild to moderate cases.

An increased number of patients who received Moxidectin Tablets developed symptomatic orthostatic hypotension with inability to stand without support after lying down for 5 minutes (in an orthostatic hypotension provocation test); 47/978 (5%) compared with 8/494 (2%) who received ivermectin. …

Moxidectin side effects

The following clinically significant adverse reactions are described in greater detail in other labeling sections:

Cutaneous, Ophthalmological and/or Systemic Adverse Reactions

Symptomatic Orthostatic Hypotension

Encephalopathy in

Loa loa

Co-infected Patients

Edema and Worsening of Onchodermatitis

Because clinical trials are conducted under varying controlled conditions, adverse reaction rates observed in one clinical trial cannot be directly compared to rates observed in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Clinical Trials Experience in Adults and Pediatric Patients (12 Years to Less than 18 Years of Age)

The safety of Moxidectin Tablets was evaluated in two randomized, double-blind, active-controlled studies in patients with confirmed onchocerciasis (Trial 1 and Trial 2)

. In Trial 1, 978 patients (including 53 pediatric patients aged 12 to less than 18 years) received Moxidectin Tablets as a single oral dose of 8 mg and 494 patients received ivermectin (including 24 pediatric patients aged 12 to less than 18 years) as a single oral dose of approximately 150 mcg/kg. In Trial 2, 127 patients aged 18 years or older received Moxidectin Tablets as a single oral dose ranging from 2 mg (this is not an approved dose) to 8 mg (38 received the recommended 8 mg dose) and 45 patients aged 18 years or older received ivermectin as a single oral dose of approximately 150 mcg/kg. …

Drug interactions

In healthy subjects, concomitant administration of a single 8 mg oral dose of Moxidectin Tablets did not have an effect on the pharmacokinetics of midazolam . Moxidectin can be co-administered with CYP3A4 substrates.

About this medicine

Moxidectin Tablets contain moxidectin, an anthelmintic drug and a macrocyclic lactone of the milbemycin class derived from the actinomycete

Streptomyces

cyanogriseus.

The chemical name of moxidectin is (2aE,4E,5'R,6R,6'S,8E,11R,13S,15S,17aR,20R,20aR,20bS)-6'-[(E)-1,3-dimethyl-1-butenyl]-5',6,6',7,10,11,14,15,17a,20,20a,20b-dodecahydro-20,20b-dihydroxy-5',6,8,19-tetramethylspiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran]-4',17(3'H)-dione 4'-(E)-(O-methyloxime). The structural formula is:

Figure

1

: Moxidectin Structure

Moxidectin is a white or pale-yellow, amorphous powder. The empirical formula is C

37H

53NO

8and the molecular weight is 639.82 Dalton. Moxidectin is readily soluble in organic solvents such as methylene chloride, diethyl ether, ethanol, acetonitrile, and ethyl acetate. It is only slightly soluble in water (0.51 mg/L) and the melting point range for moxidectin powder is 145°C to 154°C.

Moxidectin Tablets are for oral administration. Each tablet contains 2 mg of moxidectin. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6eb02ae9-9065-176f-e053-2991aa0ac891. Read the full official label on DailyMed.